FDA Approval Alert: The Need-to-Know | Liso-Cel for Relapsed/Refractory LBCL in Second Line

In June 2022, the FDA approved lisocabtagene maraleucel as treatment for relapsed/refractory large B-cell lymphoma following 1 prior line of therapy.

Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL
Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL
Video
Jul 7, 2022 8:00 PM
Catherine S. Diefenbach, MD, spoke about refining understanding of CAR T-cell therapies after the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma.
Catherine S. Diefenbach, MD, Discusses Gaps Filled by Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL
Catherine S. Diefenbach, MD, Discusses Gaps Filled by Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL
Video
Jul 1, 2022 8:00 PM
Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma who do not have chemotherapy-sensitive disease.
Catherine S. Diefenbach, MD, Reviews the Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL
Catherine S. Diefenbach, MD, Reviews the Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL
Video
Jun 29, 2022 8:00 PM
Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for the treatment of relapsed/refractory large B-cell lymphoma following 1 prior therapy.
FDA Approves Liso-Cel for Second-Line Relapsed/Refractory LBCL
FDA Approves Liso-Cel for Second-Line Relapsed/Refractory LBCL
Article
Jun 25, 2022 10:50 AM
Based on results from the phase 3 TRANSFORM trial, the FDA has approved lisocabtagene maraleucel for the second-line treatment of relapsed/refractory large B-cell lymphoma.